Posatex Otic Suspension

Posatex Otic Suspension is a triple-combination veterinary ear medication manufactured by Intervet Inc., a subsidiary of Merck Animal Health, and FDA-approved for the treatment of otitis externa in dogs. The product combines three active pharmaceutical ingredients in a single formulation: orbifloxacin, a fluoroquinolone antibiotic; mometasone furoate monohydrate, a synthetic corticosteroid; and posaconazole, a triazole antifungal agent. This combination addresses the three primary components of canine ear infections simultaneously, targeting bacterial pathogens, fungal organisms, and the inflammatory response that accompanies infection. Posatex received FDA approval under NADA 141-266 in February 2010, and it has since become a widely prescribed option for managing complicated ear infections in dogs.

Each gram of Posatex Otic Suspension contains 10 milligrams of orbifloxacin, mometasone furoate monohydrate equivalent to 1 milligram of mometasone furoate, and 1 milligram of posaconazole. These active ingredients are suspended in a mineral oil-based system containing a plasticized hydrocarbon gel, which serves as the vehicle for delivering the medication into the ear canal. The mineral oil base provides lubrication and helps the suspension adhere to the surfaces of the ear canal, promoting sustained contact between the active ingredients and the infected tissues. The formulation is available in three bottle sizes: 7.5 grams, 15 grams, and 30 grams, each fitted with a dropper tip designed for precise instillation into the canine ear canal.

The rationale behind combining three distinct pharmacological agents in a single otic preparation reflects the complex microbiology of canine otitis externa. Ear infections in dogs rarely involve a single pathogen acting in isolation. Instead, bacterial organisms such as coagulase-positive staphylococci and Pseudomonas aeruginosa frequently coexist with yeast species, particularly Malassezia pachydermatis, in the inflamed ear canal. The inflammatory response triggered by these organisms creates a warm, moist environment with altered pH and increased ceruminous secretion that further promotes microbial overgrowth. By addressing bacteria, fungi, and inflammation concurrently, Posatex targets the full pathological cycle of otitis externa rather than treating individual components in sequence.

Posatex is classified as a prescription veterinary medication, and federal law restricts its use to administration by or on the order of a licensed veterinarian. The drug is approved exclusively for use in dogs and is not labeled for food-producing animals. Extralabel use of Posatex in food-producing animals is prohibited by federal regulation. While some veterinarians may prescribe Posatex off-label for feline patients, this application falls outside the scope of the FDA-approved labeling and requires careful veterinary judgment regarding species-appropriate safety and efficacy.

The FDA-approved indication for Posatex Otic Suspension is the treatment of otitis externa in dogs caused by susceptible strains of yeast and bacteria. Otitis externa refers to inflammation and infection of the external ear canal, the tubular passage that extends from the visible ear opening to the tympanic membrane. This condition is among the most common reasons dog owners seek veterinary care, accounting for a significant proportion of dermatology-related visits in small animal practice. Dogs with pendulous ears, narrow ear canals, excessive hair growth in the canal, or those that swim frequently are predisposed to developing otitis externa due to moisture retention and reduced airflow within the ear canal.

The antibacterial spectrum of the orbifloxacin component provides coverage against the most clinically relevant bacterial pathogens involved in canine otitis externa. Orbifloxacin demonstrates activity against coagulase-positive staphylococci, which represent the most frequently isolated bacterial organisms from infected canine ears. The drug is also effective against Pseudomonas aeruginosa, a gram-negative bacterium that is notoriously difficult to treat and often associated with chronic, treatment-resistant ear infections. Additionally, orbifloxacin provides activity against Enterococcus faecalis, a gram-positive organism that can contribute to polymicrobial ear infections. This broad-spectrum antibacterial coverage addresses the majority of bacterial species encountered in routine canine otitis externa cases.

The posaconazole component targets fungal organisms in the ear canal, with particular efficacy against Malassezia pachydermatis. This lipophilic yeast is a normal commensal organism of canine skin and ear canals but can proliferate rapidly under conditions of increased moisture, altered local immunity, or disrupted skin barrier function. Malassezia overgrowth produces characteristic dark brown, waxy discharge and contributes significantly to the pruritus and discomfort associated with otitis externa. Posaconazole belongs to the triazole class of antifungals and works by inhibiting the enzyme lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Studies have demonstrated that posaconazole is at least ten times more potent than clotrimazole against canine Malassezia isolates, which informed the decision to formulate it at one-tenth the concentration used for clotrimazole in comparable otic products.

The mometasone furoate monohydrate component addresses the inflammatory dimension of otitis externa, rapidly reducing the discomfort, erythema, and swelling that characterize the condition. Inflammation in the ear canal causes pain, narrowing of the canal lumen, and increased glandular secretion, all of which impede the resolution of infection and make the dog increasingly reluctant to allow ear examination or treatment. By controlling inflammation from the first application, mometasone improves patient comfort and creates conditions more favorable for the antibacterial and antifungal components to reach infected tissues effectively. Research has demonstrated that mometasone at the concentration used in Posatex controls inflammation without producing clinically significant adrenocortical suppression when used for the recommended seven-day treatment course.

Posatex Otic Suspension is administered by instilling drops directly into the affected ear canal once daily for seven consecutive days. The dosage is determined by the dog's body weight using a straightforward two-tier dosing schedule. Dogs weighing less than 30 pounds receive four drops per affected ear per treatment, while dogs weighing 30 pounds or more receive eight drops per affected ear per treatment. Four drops deliver approximately 1.0 milligram of orbifloxacin, 0.1 milligram of mometasone furoate monohydrate, and 0.1 milligram of posaconazole. The eight-drop dose doubles these quantities proportionally for larger patients.

Proper administration technique is essential for ensuring that the medication reaches the deeper portions of the ear canal where infection resides. Before each application, the bottle should be shaken well to resuspend the active ingredients uniformly throughout the vehicle. The tip of the dropper bottle is then positioned at the opening of the ear canal, and the prescribed number of drops is instilled. After instillation, the base of the ear should be gently massaged for several seconds to distribute the suspension throughout the length of the ear canal. This massage helps the medication reach the horizontal portion of the L-shaped canine ear canal, which is the area most commonly affected by infection and the most difficult to reach with topical preparations.

The seven-day treatment duration should be completed in full even if clinical improvement is apparent before the end of the course. Premature discontinuation of antibiotic and antifungal therapy risks incomplete elimination of the causative organisms, which can lead to relapse or the development of resistant microbial populations. Owners should be counseled to continue treatment for the full prescribed duration and to return for a follow-up examination so the veterinarian can assess whether the infection has fully resolved. If no improvement is observed after the initial course, or if the infection worsens during treatment, the veterinarian should be contacted promptly to reassess the diagnosis and treatment plan.

The integrity of the tympanic membrane should be confirmed by the veterinarian before Posatex is prescribed. Because the product has not been evaluated in dogs with perforated eardrums, applying the suspension into an ear canal with a ruptured tympanic membrane could allow the medication to enter the middle ear, potentially causing ototoxicity or vestibular disturbance. If the eardrum cannot be visualized due to swelling, excessive discharge, or patient temperament, the veterinarian may need to address these barriers before initiating treatment or may choose an alternative therapeutic approach until the status of the tympanic membrane can be determined.

The pharmacological action of Posatex Otic Suspension derives from the complementary mechanisms of its three active ingredients, each targeting a different aspect of the pathology underlying canine otitis externa. This multi-pronged approach is particularly suited to ear infections because the condition involves interconnected processes of microbial colonization, immune-mediated tissue damage, and environmental changes within the ear canal that perpetuate the disease cycle. Understanding how each component works individually clarifies why the combination product achieves outcomes that single-agent therapies often cannot.

Orbifloxacin exerts its bactericidal effect through concentration-dependent inhibition of two essential bacterial enzymes: DNA gyrase and topoisomerase IV. These enzymes are required for the supercoiling, unwinding, and separation of bacterial DNA during replication and transcription. By binding to and inactivating these enzymes, orbifloxacin prevents bacterial cells from duplicating their genetic material, halting replication and ultimately causing cell death. The concentration-dependent nature of fluoroquinolone killing means that the high local concentrations achieved by direct instillation into the ear canal are particularly advantageous, as they maximize bactericidal activity against susceptible organisms while minimizing the time bacteria are exposed to sub-inhibitory concentrations that could promote resistance development.

Mometasone furoate monohydrate functions as a potent synthetic corticosteroid that modulates the inflammatory cascade at multiple levels. After diffusing into cells and binding to intracellular glucocorticoid receptors, the drug-receptor complex translocates to the nucleus and alters gene transcription, suppressing the production of pro-inflammatory cytokines, prostaglandins, and leukotrienes. This reduces vasodilation, capillary permeability, edema formation, and the migration of inflammatory cells into the affected tissue. The net clinical effect is a rapid reduction in the redness, swelling, heat, and pain that characterize inflamed ear canals. Mometasone is characterized by high topical potency with relatively low systemic bioavailability, meaning it produces strong local anti-inflammatory effects while minimizing the risk of systemic corticosteroid side effects when used topically for short durations.

Posaconazole disrupts fungal cell viability by inhibiting lanosterol 14-alpha-demethylase, a cytochrome P450-dependent enzyme essential for the biosynthesis of ergosterol. Ergosterol is a critical structural component of fungal cell membranes, analogous to cholesterol in mammalian cells. When ergosterol synthesis is blocked, the fungal cell membrane becomes depleted of this essential sterol and accumulates toxic methylated sterol precursors, compromising membrane integrity and function. This leads to increased membrane permeability, leakage of cellular contents, and eventual fungal cell death. As a triazole antifungal, posaconazole demonstrates broad-spectrum activity against yeasts and molds, and its superior potency compared to earlier azole antifungals like clotrimazole allows it to achieve effective antifungal concentrations at lower doses.

The systemic absorption of all three active ingredients from the ear canal has been characterized in radiolabeled studies using normal beagle dogs. These studies demonstrated that while some percutaneous absorption does occur, the majority of each drug remains localized within the ear canal where therapeutic action is needed. Most absorption takes place within the first few days following administration. Importantly, the degree of systemic absorption is influenced by the integrity of the epithelial barrier within the ear canal, and inflamed tissue with compromised barrier function may allow greater drug absorption than intact skin. This pharmacokinetic consideration underscores the importance of adhering to the recommended treatment duration and not exceeding the labeled dose.

Posatex Otic Suspension is generally well tolerated when used according to label directions for the recommended seven-day treatment course. The clinical field study that supported FDA approval enrolled 191 dogs with naturally occurring otitis externa and demonstrated a favorable safety profile at therapeutic doses. However, as with any pharmaceutical product containing potent active ingredients, adverse reactions can occur, and owners should be informed of potential side effects so they can monitor their dogs appropriately during treatment and report concerns to their veterinarian promptly.

The most clinically significant adverse reaction associated with Posatex is hearing loss. During the pivotal field study, one dog with bilateral otitis externa developed hearing loss during treatment. The condition resolved within approximately one week after the medication was discontinued. The product labeling includes a prominent warning that treatment should be stopped immediately if hearing loss is observed. Owners should be advised to watch for signs that may indicate auditory changes, including failure to respond to verbal commands, lack of reaction to environmental sounds, startled responses when approached from behind, or unusual head tilting. Any suspicion of hearing impairment warrants immediate cessation of the medication and veterinary evaluation.

The corticosteroid component, mometasone furoate, carries risks associated with prolonged or repeated topical corticosteroid exposure. Extended use beyond the recommended seven-day course has been linked to adrenocortical suppression and the development of iatrogenic hyperadrenocorticism, commonly known as Cushing's syndrome. The target animal safety study evaluated Posatex at one, three, and five times the clinical dose administered daily for 21 consecutive days. Dogs receiving the highest dose showed evidence of adrenal suppression based on cortisol response testing. For this reason, the labeling explicitly warns against prolonged or repeated use and recommends against using the product for durations exceeding the labeled treatment period without veterinary reassessment.

The fluoroquinolone component, orbifloxacin, is associated with a class-wide concern regarding cartilage toxicity in immature animals. Systemic administration of quinolone antibiotics has been demonstrated to produce erosion of cartilage in weight-bearing joints and other manifestations of arthropathy in young animals of multiple species. While the topical otic route of administration results in substantially lower systemic drug exposure compared to oral or injectable dosing, this concern is noted in the product labeling as a precautionary consideration, particularly for growing puppies. The clinical relevance of this warning for topical otic use at recommended doses in adult dogs is considered low, but it represents an important safety consideration for the fluoroquinolone drug class as a whole.

Additional adverse effects that owners may observe include transient local irritation at the application site, which may manifest as head shaking, ear scratching, or brief discomfort immediately following instillation. These reactions are typically mild and self-limiting. If signs of worsening infection develop during treatment, such as increased discharge, stronger odor, greater swelling, or signs of pain that intensify rather than improve, the veterinarian should be contacted to reassess the case, as treatment failure may indicate resistant organisms, an underlying primary disease, or a complication such as middle ear involvement.

Posatex Otic Suspension is contraindicated in dogs with known or suspected hypersensitivity to any of its three active ingredients or to the quinolone class of antibiotics more broadly. Dogs that have previously experienced adverse reactions to fluoroquinolone antibiotics, corticosteroids in the mometasone class, or triazole antifungal agents should not receive this product. Hypersensitivity reactions may manifest as worsening inflammation, urticaria, facial swelling, or anaphylaxis, and any dog with a history suggestive of drug allergy should be evaluated carefully before Posatex is prescribed.

The product must not be used in dogs with known perforation of the tympanic membrane. The ear canal is a closed system bounded by the eardrum at its medial end, and this membrane serves as a critical barrier preventing topical medications from entering the middle ear structures. If the tympanic membrane is ruptured, instillation of otic preparations can allow drugs to contact the delicate structures of the middle and inner ear, potentially causing ototoxicity, vestibular disturbance, or worsening of existing hearing deficits. Veterinarians should perform otoscopic examination to confirm tympanic membrane integrity before initiating treatment. In cases where the eardrum cannot be adequately visualized due to severe canal swelling or heavy discharge, pre-treatment with systemic anti-inflammatory therapy or ear cleaning under sedation may be necessary before the status of the membrane can be determined.

The safety of Posatex has not been evaluated in dogs used for breeding purposes, during pregnancy, or in lactating bitches. The corticosteroid and fluoroquinolone components both carry theoretical risks for reproductive toxicity based on class-wide data from systemic exposure studies in laboratory animals. Mometasone and related corticosteroids are known teratogens in several animal species when administered systemically during organogenesis. Fluoroquinolones can affect cartilage development in developing fetuses and neonates. While the topical otic route limits systemic exposure substantially, the absence of specific safety data in reproductive contexts means that veterinarians should weigh the benefits of treatment against potential risks when considering Posatex for pregnant, nursing, or breeding animals.

Several additional precautions guide appropriate use of this medication. Posatex should not be administered orally, as the formulation is designed exclusively for otic instillation. Concurrent use of other otic medications in the same ear should be avoided unless specifically directed by the veterinarian, as drug interactions within the ear canal have not been studied and the additional vehicle could dilute the active ingredients or alter their distribution. Posatex should be discontinued at least two weeks prior to intradermal allergy testing, as the corticosteroid component can suppress cutaneous immune responses and produce false-negative results on skin tests used to diagnose environmental allergies. Owners should be instructed to avoid contact between the medication and their own skin, eyes, and mucous membranes, and to wash hands thoroughly after each application.

While specific drug interaction studies for Posatex Otic Suspension have not been published, the pharmacological properties of its three active ingredients inform several important considerations regarding concurrent therapy. The topical otic route of administration limits systemic drug levels compared to oral or injectable dosing, which reduces but does not entirely eliminate the potential for interactions with systemically administered medications. Veterinarians should review the complete medication history of any dog before prescribing Posatex to identify potential concerns.

The corticosteroid component, mometasone furoate, warrants attention when a dog is concurrently receiving other corticosteroid medications by any route. Dogs already treated with oral prednisone, prednisolone, dexamethasone, or other systemic glucocorticoids may experience additive corticosteroid effects if Posatex is administered simultaneously, particularly if the ear canal epithelium is significantly inflamed and allows greater absorption of the topical mometasone. Similarly, dogs receiving injectable corticosteroid preparations or using topical corticosteroid products on other body areas may have elevated total corticosteroid burden. Veterinarians should consider the cumulative steroid exposure when multiple corticosteroid products are in use and may need to adjust systemic dosing or select a non-steroidal otic alternative.

Nonsteroidal anti-inflammatory drugs used concurrently with corticosteroids carry an increased risk of gastrointestinal ulceration and hemorrhage. While this interaction is most clinically relevant when both drug classes are administered systemically at therapeutic doses, the theoretical concern applies whenever a corticosteroid is absorbed into the systemic circulation. Dogs receiving chronic NSAID therapy for osteoarthritis or other conditions should be monitored for gastrointestinal signs such as decreased appetite, vomiting, dark stools, or lethargy during the Posatex treatment course, and owners should be instructed to report these signs promptly.

The fluoroquinolone component, orbifloxacin, belongs to a drug class known to interact with divalent and trivalent cation-containing products when administered orally. Oral fluoroquinolone absorption is reduced by concurrent administration of antacids, sucralfate, or supplements containing calcium, magnesium, iron, aluminum, or zinc. However, because Posatex is administered topically into the ear canal rather than ingested, this particular interaction pathway is not clinically relevant. Similarly, the systemic fluoroquinolone interaction with theophylline metabolism is unlikely to be meaningful given the low systemic absorption from otic application, but clinicians should remain aware of this class effect in patients receiving theophylline for respiratory conditions.

Posaconazole, when administered systemically, is a known inhibitor of cytochrome P450 3A4 enzymes and can increase plasma concentrations of drugs metabolized through this pathway. However, the extremely low dose of posaconazole delivered topically in the ear canal makes clinically significant CYP3A4 inhibition from Posatex use highly unlikely. The concurrent use of other otic products in the same ear should be avoided, as the addition of other liquid or ointment formulations could dilute the active ingredients in Posatex, alter the contact time of the medication with the canal surfaces, or create unpredictable chemical interactions between different vehicle systems.

Posatex Otic Suspension should be stored at controlled room temperature between 68 and 77 degrees Fahrenheit, with allowable excursions between 59 and 86 degrees Fahrenheit. The product should be kept in its original container with the cap tightly secured when not in use to prevent contamination and evaporation of the vehicle components. The bottle should be stored upright and protected from excessive heat, direct sunlight, and freezing temperatures, any of which could alter the physical stability of the suspension and potentially affect the uniform distribution of active ingredients within the vehicle. Expired medication or unused product remaining after the completion of treatment should be disposed of in accordance with local pharmaceutical waste disposal guidelines rather than discarded into household trash or flushed down drains.

Owner education regarding proper administration technique is a critical component of treatment success with Posatex. Many dog owners are unfamiliar with the anatomy of the canine ear canal and may instill drops only into the visible portion of the ear without directing the medication deep enough to reach the horizontal canal where infection resides. Veterinary staff should demonstrate the administration technique at the time of dispensing, showing the owner how to hold the ear flap, position the bottle tip, count the drops accurately, and massage the ear base to distribute the medication. Owners should also be shown what normal improvement looks like over the treatment course and counseled that complete resolution may continue after the seven-day treatment period ends.

Hygiene practices during the treatment course help prevent reinfection and protect other household members. Owners should wash their hands thoroughly with soap and water before and after each treatment session. If the dog shakes its head during or after instillation, droplets of the suspension may be distributed onto surrounding surfaces, and any contaminated areas should be cleaned promptly. The bottle tip should not contact the ear canal directly during instillation, as this can transfer organisms from the infected ear to the bottle and potentially re-inoculate the ear with contaminated medication during subsequent applications. If contact occurs, the tip should be wiped clean before the bottle is recapped.

Follow-up veterinary examination after completing the treatment course is strongly recommended to verify that the infection has fully resolved. Otitis externa can appear to improve clinically while residual organisms persist deeper in the ear canal, and premature declaration of cure without microscopic evaluation of ear cytology can lead to recurrence. The follow-up visit also provides an opportunity to identify and address any underlying predisposing factors, such as allergic skin disease, anatomical abnormalities, or endocrine disorders, that may have contributed to the development of the ear infection and could promote future episodes if left unmanaged.

The clinical effectiveness of Posatex Otic Suspension was established through a placebo-controlled, double-blinded, multi-site field study that formed the basis of the product's FDA approval. This pivotal study enrolled 191 dogs with naturally occurring otitis externa associated with both yeast and bacterial organisms. Dogs were randomly assigned to receive either Posatex or a vehicle control formulation administered once daily for six to eight days, with the dosage determined by body weight using the same four-drop and eight-drop protocol specified on the commercial label. Effectiveness was assessed through both investigator and owner evaluations at follow-up visits conducted two to seven days after the completion of treatment.

The study results demonstrated statistically significant superiority of Posatex over the vehicle control across multiple evaluation endpoints. Dogs treated with Posatex showed marked improvement in investigator-assessed clinical signs including discomfort, erythema, and swelling compared to the control group. Owner assessments corroborated these findings, with pet owners reporting greater clinical improvement in their dogs' ear condition following treatment with the active product. The effectiveness analysis supported the product's activity against the target organisms specified on the label: Malassezia pachydermatis, coagulase-positive staphylococci, Pseudomonas aeruginosa, and Enterococcus faecalis.

The component-level effectiveness of the anti-inflammatory action was evaluated separately using a mouse ear inflammation model. This study confirmed that the mometasone furoate concentration in the Posatex formulation produced significant anti-inflammatory activity, validating the inclusion of this corticosteroid at the specified concentration. The dose selection for posaconazole was supported by comparative in vitro potency studies demonstrating that posaconazole was at least ten times more potent than clotrimazole against canine Malassezia isolates. This favorable potency ratio justified formulating posaconazole at one-tenth the concentration used for clotrimazole in established otic products such as Otomax and Mometamax, which share the mometasone furoate component with Posatex.

Target animal safety was evaluated in a separate 21-day study using 44 dogs (22 males, 22 females) that received Posatex at the labeled clinical dose, at three times the clinical dose administered three times daily, at five times the clinical dose administered five times daily, or a vehicle control. This study design assessed safety margins well beyond the conditions of normal clinical use. Dogs in the highest dose group showed evidence of adrenal suppression as measured by cortisol response testing, confirming the importance of the labeling precaution against prolonged or repeated use. The safety margin between the therapeutic dose and the dose producing adverse effects in this controlled study provided confidence in the product's safety when used as directed for the recommended seven-day treatment duration.

Post-market clinical experience over more than a decade of commercial availability has further characterized the real-world safety and effectiveness profile of Posatex. The product has become a commonly prescribed option in veterinary dermatology practice, particularly for cases involving mixed bacterial and yeast infections where a single-agent approach would be insufficient. Veterinary dermatologists have noted the product's utility in managing acute flares of otitis externa in dogs with underlying allergic skin disease, where the combination of anti-infective and anti-inflammatory activity addresses both the infectious trigger and the allergic inflammatory substrate in a single application.

Dog owners frequently ask whether Posatex can be used to treat ear infections in puppies. The fluoroquinolone class of antibiotics, to which orbifloxacin belongs, has been associated with cartilage abnormalities in the weight-bearing joints of immature animals when administered systemically. While the topical otic route results in substantially lower systemic drug exposure than oral dosing, this class-wide concern is reflected in the product labeling. Veterinarians evaluate the individual patient's age, skeletal maturity, and the severity of the ear infection when determining whether Posatex is appropriate for a young dog. In some cases, alternative otic products that do not contain fluoroquinolone antibiotics may be selected for very young puppies.

Another common question involves whether ear cleaning should be performed before applying Posatex. The product labeling does not specify a mandatory ear cleaning protocol prior to application, and the field study that supported approval did not incorporate routine pre-treatment ear flushing as part of the study protocol. However, many veterinarians recommend gentle cleaning to remove excess debris and discharge before treatment begins, as heavy accumulations of cerumen and exudate can physically prevent the medication from contacting the canal epithelium. The decision to clean before treatment and the selection of an appropriate cleaning agent are best made by the attending veterinarian based on the individual case.

Owners often inquire about what to do if they miss a dose during the treatment course. Because Posatex is administered once daily, a missed dose leaves a 24-hour gap in antimicrobial and anti-inflammatory coverage. If a dose is missed, it should be administered as soon as the owner realizes the omission, and the remaining doses should continue at the normal once-daily schedule. The treatment course should still total seven complete days of application. If multiple doses have been missed, the owner should contact the veterinarian for guidance on whether to extend the treatment course or modify the therapeutic plan.

Questions about whether Posatex can be used in cats arise regularly, as feline otitis externa is also a common clinical problem. The product is FDA-approved exclusively for use in dogs, and the official labeling does not include feline dosing recommendations or safety data. Some veterinarians prescribe Posatex off-label for cats under their professional judgment, acknowledging that the product lacks formal evaluation in this species. Owners whose cats have been prescribed Posatex should follow their veterinarian's specific instructions regarding dose and duration, as feline ears differ anatomically and physiologically from canine ears, and absorption characteristics may differ.

The question of whether recurring ear infections indicate that Posatex is not working reflects a misunderstanding of the distinction between treatment failure and recurrence driven by underlying disease. Posatex is designed to resolve acute episodes of otitis externa caused by susceptible organisms, and it typically accomplishes this goal within the seven-day treatment course. Recurrent infections after successful treatment usually indicate the presence of a predisposing condition such as atopic dermatitis, food allergy, hypothyroidism, or conformational factors that create a favorable environment for repeated microbial colonization. Addressing these underlying causes is essential for long-term ear health and is separate from the antimicrobial role of Posatex in managing individual episodes.